Liquidia's stock dropped 57% after a legal loss in its patent dispute with United Therapeutics.
Liquidia Corporation's shares fell sharply following a court ruling that favored United Therapeutics Corporation (UTHR). This decision affects Liquidia's market position and revenue potential. As of the last close, Liquidia's shares were priced at $541.43, reflecting a significant decline from earlier trading levels.
Investor takeaway: Keep an eye on the ongoing patent litigation developments, as they may impact related companies.
Advertisement
United Therapeutics Corporation
UTHR.US
UTHR.US
United Therapeutics Corporation
WealthAwesomeMarket cap
$23.01B
P/E
19.2x
52W high
$609.35
52W low
$409.07
1W change
+10.47%
Beta
0.49
Analyst Price Targets
Based on 15 analysts covering UTHR · as of Oct 5, 2026
Wall Street analysts forecast UTHR stock price to rise 20.1% over the next 12 months.
Consensus
Buy4.13 / 5.00
Avg. Target
C$644.36
+20.1% Upside
Current Price
C$536.40
Last close
Analyst Breakdown (15 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on UTHR's historical volatility
30-Day Vol
47.6%
Annualized
90-Day Vol
32.4%
Annualized
Trend (90d)
-8.3%
Annualized drift
90d Mean
C$520.80
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$531.15 | C$450.73 – C$625.91 |
| 60 trading days | C$525.95 | C$416.98 – C$663.39 |
| 90 trading days | C$520.80 | C$391.91 – C$692.08 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Liquidia's 57% Decline Stands Out
The drop in Liquidia's stock highlights investor concerns over patent protections.
Liquidia Faces Major Setback in Patent Litigation
Liquidia's stock plummeted 57% after a court ruled in favor of United Therapeutics in a patent dispute over Yutrepia. This outcome significantly affects Liquidia's potential market share in the therapeutic sector. The company's last close was $541.43, and the stock has traded within a 52-week range of $409.07 to $609.35, indicating a substantial loss of value. The recent ruling may shake investor confidence in Liquidia's future prospects.
Advertisement
Stock Performance and Market Reaction
Following the ruling, Liquidia's trading volume reached 160,984 shares, notably lower than the 20-day average of 935,380 shares. This decrease suggests a decline in investor interest after the negative news. Over the past week, Liquidia's stock had shown a slight increase of 10.47%, but the recent drop has overshadowed that momentum. Year-to-date, the stock is up 7.99%, but recent developments could change that trend.
What’s Next for Liquidia and UTHR?
Looking ahead, investors will closely monitor any further developments in the patent litigation, as they could significantly impact both Liquidia and United Therapeutics. The average analyst target for United Therapeutics is $644.36, suggesting a potential upside of 19% from current levels. With a P/E ratio of 19.212 and a market cap of approximately $23 billion, United Therapeutics may continue to attract interest. Liquidia's future performance will heavily depend on how it navigates this legal landscape.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
